一项评估脂蛋白 (a) 降低 Pelacarsen (TQJ230) 对德国高脂蛋白血症 (a) 和已确诊心血管疾病患者每周脂蛋白单采术率的影响的多中心试验
一项随机、双盲、安慰剂对照、多中心试验,评估在德国接受每周脂蛋白单采术的高脂蛋白血症 (a) 和确定的心血管疾病患者使用 Pelacarsen (TQJ230) 治疗后与安慰剂相比脂蛋白单采术率的降低
研究概览
详细说明
研究类型
注册 (实际的)
阶段
- 第三阶段
联系人和位置
学习地点
-
-
-
Berlin、德国、13353
- Novartis Investigative Site
-
Cloppenburg、德国、49661
- Novartis Investigative Site
-
Erlangen、德国、91054
- Novartis Investigative Site
-
Mainz、德国、55131
- Novartis Investigative Site
-
Ulm、德国、89081
- Novartis Investigative Site
-
-
Baden-Wurttemberg
-
Villingen-Schwenningen、Baden-Wurttemberg、德国、78052
- Novartis Investigative Site
-
-
Bavaria
-
Munich、Bavaria、德国、81377
- Novartis Investigative Site
-
Würzburg、Bavaria、德国、97080
- Novartis Investigative Site
-
-
Hesse
-
Frankfurt am Main、Hesse、德国、60431
- Novartis Investigative Site
-
-
Lower Saxony
-
Göttingen、Lower Saxony、德国、37075
- Novartis Investigative Site
-
-
North Rhine-Westphalia
-
Düsseldorf、North Rhine-Westphalia、德国、42010
- Novartis Investigative Site
-
Geilenkirchen、North Rhine-Westphalia、德国、52511
- Novartis Investigative Site
-
-
Saxony
-
Dresden、Saxony、德国、01307
- Novartis Investigative Site
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
描述
纳入标准:
- 目前在德国接受脂蛋白单采术分离 Lp(a) 的患者在筛选前每周 ≥ 12 个月,并且在随机分组前的过去 52 周内至少进行了 40 次治疗
- 筛选时脂蛋白 (a) (Lp(a)) > 60 mg/dL
- 自发性既往心肌梗死 (MI):筛查访视后 ≥ 3 个月至筛查访视前 ≤ 10 年,和/或
- 缺血性中风:筛查访视后 ≥ 3 个月至筛查访视前 ≤ 10 年,和/或
- 有临床意义的症状性外周动脉疾病 (PAD)
排除标准:
- 不受控制的高血压
- 心力衰竭纽约心脏协会 (NYHA) IV 级
- 任何器官系统的恶性病史
- 出血性中风或其他大出血史
- 血小板计数
- 活动性肝病或肝功能障碍
- 显着的肾脏疾病
- 孕妇或哺乳期妇女
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:四人间
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Pelacarsen (TQJ230)
Pelacarsen (TQJ230) 80 mg s.c.
Q4W
|
Pelacarsen (TQJ230) 80 mg 皮下注射
Q4W
其他名称:
|
|
安慰剂比较:Placebo
Placebo to Pelacarsen s.c. Q4W
|
安慰剂对佩拉卡森
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Rate of Lipoprotein Apheresis Sessions Performed Over 52 Weeks Normalized to the Weekly Lipoprotein Apheresis Schedule
大体时间:Up to Week 52
|
Rate (proportion) of apheresis sessions was calculated as the number of actual lipoprotein apheresis (LA) sessions received, divided by the number of planned LA sessions during the 52-week period, which is 52 for patients who completed all study visits, or pro-rated for those who discontinued early.
This rate could range from 0 to 1, with 0 indicating that the patient had skipped all planned LA sessions, and 1 indicating that the patient had received all planned sessions.
Multiple imputation for missing Lp(a) data was performed, and missing apheresis data was imputed.
|
Up to Week 52
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Time to Lipoprotein Apheresis Avoidance
大体时间:From randomization up to Week 52
|
Lipoprotein apheresis avoidance is defined as at least 24 consecutive weeks of no lipoprotein apheresis until end of study.
|
From randomization up to Week 52
|
|
Number of Participants With Total Lipoprotein Apheresis Avoidance From Week 12 to Week 52
大体时间:Week 12 up to Week 52
|
Total lipoprotein apheresis avoidance is defined as no apheresis performed from Week 12 to Week 52.
|
Week 12 up to Week 52
|
|
Change From Baseline to Week 52 in the Log-transformed Lp(a) Reported as mg/dL
大体时间:Baseline, week 52
|
Week 52 / Baseline ratio in Lp(a) of pelacarsen (TQJ230) vs placebo reported as particle mass (mg/dL).
Baseline Lp(a) was defined as the last non-missing pre-lipoprotein apheresis assessment prior to the first dose of randomized study drug.
|
Baseline, week 52
|
|
Change From Baseline to Week 52 in the Log-transformed Lp(a) Reported as Nmol/L
大体时间:Baseline, week 52
|
Week 52 / Baseline ratio in Lp(a) of pelacarsen (TQJ230) vs placebo reported as molar concentration (nmol/L).
Baseline Lp(a) was defined as the last non-missing pre-lipoprotein apheresis assessment prior to the first dose of randomized study drug.
|
Baseline, week 52
|
其他结果措施
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Rate of Lipoprotein Apheresis Sessions From Week 12 to Week 52 and Week 24 to Week 52 Normalized to the Weekly Lipoprotein Apheresis Schedule
大体时间:Week 12 to 52, Week 24 to 52
|
Rate (proportion) of apheresis sessions is calculated using the following formula: the total number of apheresis sessions performed over the double-blinded treatment period/total weeks from Week12 to Week52 or total weeks from Week24 to Week52.
Multiple imputation for missing Lp(a) data was performed and missing apheresis data were imputed.
|
Week 12 to 52, Week 24 to 52
|
|
Number of Participants With Total Lipoprotein Apheresis Avoidance From Week 24 to Week 52
大体时间:Week 24 to Week 52
|
Number of participants with no apheresis performed between week 24 to week 52.
|
Week 24 to Week 52
|
|
Time-averaged Lp(a) Levels Reported as mg/dL
大体时间:Baseline, Week 52
|
Time averaged Lp(a) levels were calculated as CAVG = CMIN + 0.73 × (CMAX-CMIN), where CMAX and CMIN are the immediate pre- and post-apheresis Lp(a) levels.
|
Baseline, Week 52
|
|
Time-averaged Lp(a) Levels Reported as Nmol/L
大体时间:Baseline, Week 52
|
Time averaged Lp(a) levels were calculated as CAVG = CMIN + 0.73 × (CMAX-CMIN), where CMAX and CMIN are the immediate pre- and post-apheresis Lp(a) levels.
|
Baseline, Week 52
|
|
Percentage Change in Total Cholesterol, LDL-C, High-density Lipoprotein-Cholesterol (HDL-C), Non-HDL-C, Very-low-density Lipoprotein-Cholesterol (VLDL-C), apoB and Triglycerides (Pre- Lipoprotein Apheresis) From Baseline to Week 52
大体时间:Baseline, Week 52
|
Evaluate the change in expanded lipid profile parameters measured in mg/dL
|
Baseline, Week 52
|
|
Change From Baseline to Week 52 in the Physical Health Summary Score for the SF-36 Questionnaire
大体时间:Baseline, Week 52
|
The Short Form-36 Physical Component Summary (SF-36 PCS) is an instrument to measure health-related quality of life among healthy patients and patients with acute and chronic conditions. It consists of eight subscales (domains) that can be scored individually: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role- Emotional, and Mental Health. The outcome of the questionnaires in eight scales results in two summary scores, physical component and mental component, both ranging from 0 - 100. Higher scores indicate a higher level of functioning. A positive change from baseline score indicates an improvement. |
Baseline, Week 52
|
|
Change From Baseline to Week 52 in the Mental Health Summary Score for the SF-36 Questionnaire
大体时间:Baseline, Week 52
|
The Short Form-36 Physical Component Summary (SF-36 PCS) is an instrument to measure health-related quality of life among healthy patients and patients with acute and chronic conditions. It consists of eight subscales (domains) that can be scored individually: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role- Emotional, and Mental Health. The outcome of the questionnaires in eight scales results in two summary scores, physical component and mental component, both ranging from 0 - 100. Higher scores indicate a higher level of functioning. A positive change from baseline score indicates an improvement. |
Baseline, Week 52
|
|
Patient Preference Questionnaire
大体时间:Baseline, Week 52
|
Participants were asked for their treatment preference between weekly lipoprotein apheresis or monthly self-injection.
The number of participants that prefer each option at baseline and 52 weeks is reported.
|
Baseline, Week 52
|
合作者和调查者
调查人员
- 研究主任:Novartis Pharmaceuticals、Novartis Pharmaceuticals
出版物和有用的链接
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- CTQJ230A12302
- 2021-003059-41 (EudraCT编号)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.